Similar Search Results

The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals

Glennie, Judith L.; Torrance, George W.; Baladi, Jean … - In: PharmacoEconomics 15 (1999) 5, pp. 459-468

The first edition of the Guidelines for Economic Evaluation of Pharmaceuticals: Canada was published in November 1994. At that time, the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) was assigned the task of maintaining and regularly updating the Canadian Guidelines....

Persistent link: https://www.econbiz.de/10005449189

Hospital Length of Stay for Schizophrenia: Is Primary Payer an Influencing Factor?

Sclar, David A.; Robison, Linda M.; Skaer, Tracy L.; … - In: Disease Management and Health Outcomes 5 (1999) 6, pp. 339-347

Objective: The purpose of this study was 3-fold: (i) to determine the distribution of US patients diagnosed with schizophrenia and requiring a hospitalisation in the calendar year 1988 or 1992, by primary payer type (Medicare; Medicaid; or private insurance); (ii) to discern the mean inpatient...

Persistent link: https://www.econbiz.de/10005590212

Actual Costs Versus Diagnostic-Related Group Reimbursements for Unstable Angina: An Important Distinction for Effective Disease Management

Brunelli, Claudio; Bezante, Gian Paolo; Pasdera, Alberto; … - In: Disease Management and Health Outcomes 5 (1999) 4, pp. 225-232

regarding diagnostic and therapeutic procedures for these patients compared with the reimbursement rates established by the … to gather all the information necessary to establish whether reimbursement rates are covering real costs and to initiate …

Persistent link: https://www.econbiz.de/10005448793

Using Pharmacoeconomic Analysis to Make Drug Insurance Coverage Decisions

Anis, Aslam H.; Rahman, Tuhin; Schechter, Martin T. - In: PharmacoEconomics 13 (1998) 1 Part 2, pp. 119-126

Our objective was to institute a cost-effectiveness-based reimbursement eligibility and coverage scheme for drugs in … are based on a critical evaluation of pharmacoeconomic studies submitted by manufacturers seeking reimbursement … with a similar process, with cost-effectiveness criteria for reimbursement eligibility. However, analysis in that province …

Persistent link: https://www.econbiz.de/10005449089

Managing Pharmaceutical Expenditure while Increasing Access: The Pharmaceutical Management Agency (PHARMAC) Experience

Braae, Richard; McNee, Wayne; Moore, David - In: PharmacoEconomics 16 (1999) 6, pp. 649-660

The role of the Pharmaceutical Management Agency (PHARMAC) is to manage pharmaceutical subsidy expenditure in New Zealand. PHARMAC has adopted a proactive approach. It selects the drugs that are to be subsidised and declines to subsidise others. It has established reference pricing across many...

Persistent link: https://www.econbiz.de/10005449322

The Selection of Data Sources For Use in Modelling Studies

Nuijten, Mark J.C. - In: PharmacoEconomics 13 (1998) 3, pp. 305-316

Economic analysis has become increasingly important in healthcare in general, and particularly with respect to pharmaceuticals. Therefore, it is vital that the methods used in such evaluations are carefully scrutinised and refined. However, guidelines contain only a limited number of...

Persistent link: https://www.econbiz.de/10005449056

Retrospective Economic and Outcomes Analyses Using Non-US Databases: A Review

Shi, Lizheng; Wu, Eric Q; Hodges, Meredith; Yu, Andrew; … - In: PharmacoEconomics 25 (2007) 7, pp. 563-576

Retrospective database analyses pose a series of methodological challenges, some of which are unique to their data sources, particularly in countries outside the US. This study aimed to qualitatively review the methodological challenges of using non-US databases to conduct retrospective economic...

Persistent link: https://www.econbiz.de/10005243205

Enhancing Outcomes Research: The Experience of a Community Pharmacist Research Network

Longe, R. Leon; Taylor, A. Thomas; Wade, William E.; … - In: Disease Management and Health Outcomes 6 (1999) 5, pp. 261-268

The emphasis on healthcare in the US is shifting to the ambulatory environment. To date, few studies have evaluated the effects that community pharmacists have on patient care. In an attempt to address this issue, 4 academicians from a college of pharmacy developed a research network of...

Persistent link: https://www.econbiz.de/10005404631

Outcome Measures for Pharmacoeconomics Education

Maio, Vittorio; Lofland, Jennifer H. - In: PharmacoEconomics 22 (2004) 8, pp. 549-550

Persistent link: https://www.econbiz.de/10005590394

Outcomes, Outcomes Research and Disease Management: A View from the UK

Walley, Tom - In: Disease Management and Health Outcomes 5 (1999) 4, pp. 197-207

The UK National Health Service (NHS) is in the process of further reforms aimed at restoring a national focus to its activities and also at enhancing the quality of the service it provides. Key features are: 1. the formation of primary care groups to replace general practitioner (GP)...

Persistent link: https://www.econbiz.de/10005448825